Key Points:
- A clinical trial of 500 patients revealed that the daily experimental pill daraxonrasib doubles overall survival time for metastatic pancreatic cancer.
- Patients taking the oral drug survived a median of 13.2 months, compared to just 6.6 to 6.7 months for patients receiving standard chemotherapy.
- Daraxonrasib targets KRAS mutations, which drive over 90% of pancreatic cancers and were previously considered “undruggable” for more than forty years.
- The therapy cut the risk of death by 60% and produced significantly fewer severe side effects than conventional toxic chemotherapy regimens.
In the medical community, a daily pill has doubled the survival time of patients battling metastatic pancreatic cancer, one of the world’s deadliest and most stubborn malignant diseases. Oncologists presenting at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on May 31, 2026, hailed the arrival of the drug, known as daraxonrasib. For decades, clinicians have had virtually no effective treatments to offer patients diagnosed with advanced pancreatic ductal adenocarcinoma, making this new milestone a historic leap forward.
The findings come from a large-scale, randomized Phase 3 trial called RASolute 302, which enrolled 500 patients at sites worldwide. All of the participants had already undergone at least one round of standard chemotherapy, only to watch their tumors progress. Researchers divided the patients into two groups: one received standard investigator-selected chemotherapy, while the other received a daily oral dose of 300 mg of daraxonrasib. Simultaneously published in the New England Journal of Medicine, the resulting data completely outperformed historical benchmarks.
Patients who took daraxonrasib lived for a median of 13.2 months, while those on standard chemotherapy survived for an average of just 6.6 to 6.7 months. This means the daily pill successfully doubled overall survival time. In addition, the targeted therapy reduced the overall risk of death by 60% across the trial population. Doctors also measured progression-free survival—the duration of time before a patient’s tumor begins to grow or spread again. Daraxonrasib kept the deadly tumors in check for a median of 7.2 months, whereas standard chemotherapy regimens failed much faster.
Developed by the biotechnology firm Revolution Medicines, daraxonrasib (formerly known as RMC-6236) works by inhibiting the active state of RAS proteins. The KRAS gene is the primary driver in more than 90% of pancreatic ductal adenocarcinoma cases. When mutated, this gene locks cells into a state of continuous, aggressive growth, fueling tumor development. For more than four decades, scientists labeled KRAS as “undruggable” because its smooth, spherical shape lacked convenient pockets for conventional drugs to bind. Daraxonrasib bypasses this historic hurdle by forming a tri-complex that blocks downstream cancer signaling.
The dramatic clinical benefits triggered powerful emotional reactions among seasoned oncologists who have spent their careers treating this lethal disease. Dr. Rachna Shroff, the chief of oncology at the University of Arizona Cancer Center and an independent ASCO gastrointestinal expert, admitted that she started crying in her clinic when she first read the trial results. Shroff described the study as “landscape-changing” and proof that targeting KRAS in pancreatic cancer is finally a practical reality. Dr. Julie Gralow, the chief medical officer of ASCO, went even further, describing the study not just as a standard home run but as an outright grand slam for oncology.
Beyond extending lives, the oral pill significantly improved the quality of daily life for trial participants. Traditional chemotherapy cocktails—such as FOLFIRINOX or gemcitabine plus nab-paclitaxel—routinely flood the patient’s entire body with toxins, causing severe hair loss, extreme fatigue, neuropathic pain, and dangerous drops in white blood cell counts. By contrast, daraxonrasib selectively targets mutated cancer cells. Patients taking the pill reported far fewer severe side effects, with most experiencing manageable rashes, mild mouth sores, or temporary diarrhea, allowing them to spend their remaining months in comfort rather than in hospital wards.
The success of daraxonrasib also offers massive hope for patients fighting other stubborn forms of cancer. Beyond pancreatic tumors, mutated KRAS genes drive a significant portion of non-small cell lung cancers and colorectal cancers. Researchers have already initiated Phase 1 and Phase 2 trials to evaluate the pill’s effectiveness in treating these other solid tumors. The ability to successfully target active RAS proteins could pave the way for a broader therapeutic revolution, completely shifting how doctors treat mutated cancers that were once considered terminal death sentences.
Following these unprecedented trial results, Revolution Medicines is preparing to submit the drug for formal global regulatory approvals. The U.S. Food and Drug Administration (FDA) has already granted daraxonrasib both breakthrough therapy and orphan drug designations. Recognizing the urgent need for this treatment, the manufacturer has also established an Expanded Access Program to make the daily pill available to eligible adult patients who cannot join ongoing clinical trials and have no other viable treatment options. While scientists continue to study combinations to make the drug’s effects last even longer, this milestone marks the beginning of a brand-new era in the fight against pancreatic cancer.
